Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women

Helen M Macdonald, Adrian D Wood, Lorna S Aucott, Alison J Black, William D Fraser, Alexandra Mavroeidi, David M Reid, Karen R Secombes, William G Simpson, Frank Thies

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Few year-long vitamin D supplementation trials exist that match seasonal changes. The aim of this study was to determine whether daily oral vitamin D3 at 400 IU or 1000 IU compared with placebo affects annual BMD change in postmenopausal women in a 1-year double blind placebo controlled trial in Scotland. Caucasian women aged 60-70 y (n = 305) were randomized to one of two doses of vitamin D or placebo. All participants started simultaneously in January/February 2009, attending visits at bi-monthly intervals with 265 (87%) women attending the final visit; and an additional visit 1 month after treatment cessation. BMD (Lunar iDXA) and 1,25-dihydroxyvitamin D[1,25(OH)2 D], N-terminal propeptide of type 1 collagen [P1NP], C-terminal telopeptide of type I collagen [CTX] and fibroblast growth factor-23 [FGF23] were measured by immunoassay at the start and end of treatment. Circulating PTH, serum Ca and total 25-hydroxyvitamin D [25(OH)D] (latter by tandem mass spectrometry) were measured at each visit. Mean BMD loss at the hip was significantly less for the 1000 IU vitamin D group (0.05 ± 1.46%), compared to the 400 IU vitamin D or placebo groups (0.57 ± 1.33% and 0.60 ± 1.67%, respectively) (p 
Original languageEnglish
Pages (from-to)2202-2213
Number of pages12
JournalJournal of Bone and Mineral Research
Volume28
Issue number10
Early online date18 Sep 2013
DOIs
Publication statusPublished - Oct 2013

    Fingerprint

Keywords

  • vitamin D
  • randomised controlled trial
  • bone loss
  • bone turnover markers
  • postmenopausal women

Cite this